menu
    • menu

    Company profile for Ascletis Pharma

    NEW Drugs in Dev: 25
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ascletis’ mission：Innovative cures liberate life to the fullest. Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Ascletis’ vision ：To become the most innovative world-class biomedical company. Led by a management team with deep expertise and a proven track record, we have developed an integrated platfor...
    Ascletis’ mission：Innovative cures liberate life to the fullest. Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Ascletis’ vision ：To become the most innovative world-class biomedical company. Led by a management team with deep expertise and a proven track record, we have developed an integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ascletis PharmaChina Flag
    Country
    Country
    China
    Address
    Address
    1785 Jianghai Rd, Bldg No.1, Ste 804, Binjiang District, Hangzhou, Zhejiang
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ascletis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascletis Advances ASC30-ASC39 Combo for Clinical Trials
    Ascletis Advances ASC30-ASC39 Combo for Clinical Trials

    07 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-fixed-dose-combination-of-asc30-once-daily-oral-small-molecule-glp-1r-agonist-and-asc39-once-daily-oral-small-molecule-amylin-selective-amylin-receptor-agonist-for-clinical-development-302735615.html

    PR NEWSWIRE
    07 Apr 2026
    Share Share
    Ascend Pharma's ASC39 Shows Eloralintide-Like Amylin Selectivity
    Ascend Pharma's ASC39 Shows Eloralintide-Like Amylin Selectivity

    17 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oral-small-molecule-amylin-receptor-agonist-asc39-demonstrated-eloralintide-like-amylin-selectivity-and-efficacy-in-preclinical-models-302715843.html

    PR NEWSWIRE
    17 Mar 2026
    Share Share
    Ascletis Reports Positive Phase II Results of ASC30 for Obesity
    Ascletis Reports Positive Phase II Results of ASC30 for Obesity

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-ii-24-week-study-for-its-ultra-long-acting-subcutaneous-depot-formulations-of-small-molecule-glp-1r-agonist-asc30-for-obesity-302709245.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share
    Ascletis Eyes Quarterly GLP-1 Dosing Following Phase 2 Readout
    Ascletis Eyes Quarterly GLP-1 Dosing Following Phase 2 Readout

    10 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ascletis-posts-phase-2-obesity-data-touts-potential-quarterly-glp-1-dosing

    FIERCE BIOTECH
    10 Mar 2026
    Share Share
    Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36
    Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36

    10 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-selects-oral-amylin-receptor-peptide-agonist-asc36-for-clinical-development-302683756.html

    PR NEWSWIRE
    10 Feb 2026
    Share Share
    Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH
    Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230125/0/en/Sagimet-Announces-Positive-52-Week-Data-from-License-Partner-Ascletis-Open-Label-Phase-3-Clinical-Trial-Evaluating-the-Long-Term-Safety-of-ASC40-Denifanstat-Tablets-in-Patients-wit.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search